Pluristem Selected to Present at International Society for Experimental Hematology Meeting.

HAIFA, Israel -- Pluristem Life Systems, Inc. (OTCBB: PLRS) announces they have been chosen to present at the 35th Annual Scientific Meeting of the International Society for Experimental Hematology in Minneapolis, Minnesota September 27- 30, 2006. The meeting will highlight the important role and personal impact the Society has made in the field of experimental hematology. Speakers from around the world will gather with Ora Burger, VP R&D of Pluristem Life Systems, chosen to discuss the stem cell product PLX-I, Pluristem's potential breakthrough solution that could be used to replace the traditional bone marrow transplant search and match process.

Zami Aberman, Pluristem CEO, states, "Pluristem has been chosen from many other stem cell companies because of the true breakthrough we believe we have achieved regarding bone marrow transplants. We will take the opportunity to address our colleagues in the scientific community that sufficient engraftment is definitely possible with a limited number of hematopoietic stem cells available in a single portion of umbilical cord blood. Our PLX-I product paves the way towards using umbilical cord blood instead of bone marrow transplants for adult patients. It improves the effectiveness of engraftments and shortens recovery times. If additional animal studies and human clinical trials prove equally successful, our PLX-I product could lead to wider use in bone marrow transplants and various types of blood cancer. Nearly 100,000 people could benefit from this treatment annually."

About Pluristem

Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

www.pluristem.com/default.asp

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include statements: that our company will discuss the stem cell product PLX-I at the Hematology conference, that Pluristem has achieved a breakthrough solution that could be used to replace the traditional bone marrow transplant search and match process; that sufficient engraftment is definitely possible with a limited number of hematopoietic stem cells available in a single portion of umbilical cord blood;that our PLX-1 product paves the way towards using umbilical cord blood instead of bone marrow transplants for adult patients improving the effectiveness of engraftments and shortening recovery times;that if additional animal studies and human clinical trials prove equally successful, our PLX-I product could lead to wider use in bone marrow transplants and various types of blood cancer; that we expect our first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation; and our first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation. Factors which may significantly change or prevent our forward looking statements from fruition include that the Congress may not proceed; that our VP Ora Burger may not be able to appear and speak for some reason; that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.